Mesalamine maintenance therapy for Crohn's disease [1] (multiple letters)

Gastroenterology

Volumn 120, Issue 2, 2001, Pages 585-586

  Feagan, B G ^a   McDonald, J W D ^a   Cottone, M ^a   Camma C ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE;

CHRONIC DISEASE; CLINICAL TRIAL; COLON DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; FOLLOW UP; HUMAN; LETTER; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RESOURCE ALLOCATION;

EID: 0035129371     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.22159     Document Type: Article

References (5)

1. C Cammà M Giunta M Rosselli M. Cottone Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis ad-justed for confounding variables Gastroenterology 113 1997 1465 1473
2. LR Sutherland Mesalamine for the prevention of postoperative recurrence: is nearly there the same as being there? (editorial) Gastroenterology 118 2000 436 438
3. R Caprilli A Andreoli L Capurso Oral mesalazine (5-amino-salicylic acid; Asacol) for the prevention of post-operative recur-rence of Crohn's disease Aliment Pharmacol Ther 8 1994 35 43
4. BG Feagan JW McDonald JJ Koval Therapeutics and inflamma-tory bowel disease: a guide to the interpretation of randomized controlled trials Gastroenterology 110 1996 275 283
5. RBC Peto Trials: the next 50 years. Large scale randomised evidence of moderate benefits Br Med J 317 1998 1170 1171